CN112262213A - 新型抗pad2抗体 - Google Patents

新型抗pad2抗体 Download PDF

Info

Publication number
CN112262213A
CN112262213A CN201980038636.6A CN201980038636A CN112262213A CN 112262213 A CN112262213 A CN 112262213A CN 201980038636 A CN201980038636 A CN 201980038636A CN 112262213 A CN112262213 A CN 112262213A
Authority
CN
China
Prior art keywords
antibody
pad
pad2
present
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980038636.6A
Other languages
English (en)
Chinese (zh)
Inventor
齐藤宪二
坂田知子
川野边峻哲
古贺启太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fumar Corp
Original Assignee
Fumar Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumar Corp filed Critical Fumar Corp
Publication of CN112262213A publication Critical patent/CN112262213A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03015—Protein-arginine deiminase (3.5.3.15)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980038636.6A 2018-06-20 2019-06-19 新型抗pad2抗体 Pending CN112262213A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018117142 2018-06-20
JP2018-117142 2018-06-20
PCT/JP2019/024310 WO2019244934A1 (ja) 2018-06-20 2019-06-19 新規抗ｐａｄ２抗体

Publications (1)

Publication Number Publication Date
CN112262213A true CN112262213A (zh) 2021-01-22

Family

ID=68984058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038636.6A Pending CN112262213A (zh) 2018-06-20 2019-06-19 新型抗pad2抗体

Country Status (6)

Country Link
US (1) US20210246225A1 (enExample)
EP (1) EP3816289A4 (enExample)
JP (2) JP7084057B2 (enExample)
CN (1) CN112262213A (enExample)
CA (1) CA3102360A1 (enExample)
WO (1) WO2019244934A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001407A (zh) * 2024-04-02 2024-05-10 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023191035A1 (ja) 2022-03-31 2023-10-05 株式会社ファーマフーズ 線維化の抑制のための組成物又は方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140127720A1 (en) * 2012-11-05 2014-05-08 The Johns Hopkins University Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
WO2014086365A1 (en) * 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CN104360070A (zh) * 2014-11-28 2015-02-18 山东创新药物研发有限公司 肽基精氨酸脱亚胺酶2在制备肿瘤临床诊断试剂中的应用
WO2016155745A1 (en) * 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2005100604A2 (en) * 2004-04-01 2005-10-27 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
WO2007095250A2 (en) * 2006-02-13 2007-08-23 The Cleveland Clinic Foundation Compositions and methods for inhibiting optic nerve damage
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
JP5528436B2 (ja) * 2008-06-04 2014-06-25 モディクエスト べー．フェー． 抗炎症剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140127720A1 (en) * 2012-11-05 2014-05-08 The Johns Hopkins University Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
WO2014086365A1 (en) * 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
US20150376294A1 (en) * 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CN104360070A (zh) * 2014-11-28 2015-02-18 山东创新药物研发有限公司 肽基精氨酸脱亚胺酶2在制备肿瘤临床诊断试剂中的应用
WO2016155745A1 (en) * 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"protein-arginine deiminase type-2 [Homo sapiens]", 《GENBANK》 *
DRES DAMGAARD等: "Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay", 《JOURNAL OF IMMUNOLOGICAL METHODS》 *
李昌等: "PADI2与人多种肿瘤的遗传易感性的关系", 《山东大学学报（医学版）》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001407A (zh) * 2024-04-02 2024-05-10 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用

Also Published As

Publication number Publication date
JP7084057B2 (ja) 2022-06-14
EP3816289A1 (en) 2021-05-05
CA3102360A1 (en) 2019-12-26
JP2022119899A (ja) 2022-08-17
EP3816289A4 (en) 2022-03-02
US20210246225A1 (en) 2021-08-12
WO2019244934A1 (ja) 2019-12-26
JP7411264B2 (ja) 2024-01-11
JPWO2019244934A1 (ja) 2021-06-24

Similar Documents

Publication Publication Date Title
US20230192890A1 (en) Novel anti-pad4 antibody
JP2021184731A (ja) Ｃｄ１２７に対する抗体
TWI635097B (zh) 新穎抗人類ｔｓｌｐ受體抗體
US11548938B2 (en) DbpA antibodies and uses thereof
CN110072891A (zh) 抗人cd73抗体
JP7624185B2 (ja) 新規抗ｐａｄ４抗体
KR20230135691A (ko) 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도
WO2018089508A2 (en) Anti-cd47 antibodies
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
WO2021183717A1 (en) Proteinaceous therapeutics
US11773177B2 (en) Variant antibodies that bind OX40
CN112930195B (zh) 抗人Fn14抗体
CN112375145A (zh) 人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
TW202035455A (zh) 抗ｏｘ４０抗體、其抗原結合片段及其醫藥用途
JP7411264B2 (ja) 新規抗ｐａｄ２抗体
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
JP2007527703A (ja) 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー
JP2025118995A (ja) 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
JP2025525492A (ja) 新規なｔｃｔｐ結合分子
WO2026002198A1 (zh) 抗cd25抗体及其应用
CN121226552A (zh) 抗cd25抗体及其应用
CN120897928A (zh) 针对犬il-4的犬抗体
KR20210116113A (ko) c-Myc 펩타이드 특이적인 항체 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination